Development Of Liposarcoma Research Articles

High expression of apoptosis-related LMNB2 predicts an unfavorable outcome: A potential prognostic biomarker for liposarcoma

Liposarcoma (LPS) is the most prevalent soft-tissue sarcoma and the second most common malignant mesenchymal sarcoma. Molecular markers have proven instrumental in guiding the diagnosis, prognosis, and treatment strategies for LPS patients. Identifying potential therapeutic targets is essential for developing effective intervention strategies for LPS. LMNB2, an apoptosis-related gene, exhibits associations with various tumors. Therefore, exploring the feasibility of LMNB2 as a prognostic biomarker for LPS is crucial. After screening for differentially expressed genes (DEGs), which were analyzed by GEO2R, 14 apoptosis-related genes were obtained by overlapping DEGs from the GSE21122 and GSE159659 datasets. SPSS software was used for univariate analysis. Receiver operating characteristic curves were constructed by GraphPad software to compare the expression of LMNB2 between LPS and normal tissues. Kaplan–Meier curves were generated to verify the correlation between LMNB2 expression and survival time. GeneMANIA and STRING were used to construct LMNB2-related gene-gene and protein–protein interaction networks. Hiplot software facilitated function and pathway enrichment analysis to determine the potential mechanism of LMNB2-mediated LPS progression. CIBERSORT was used to evaluate the correlation between LMNB2 expression and immune cell infiltration. The expression level of LMNB2 was significantly higher in LPS, and the high expression of LMNB2 was significantly related to poor prognosis in LPS patients. Further analysis indicated that LMNB2 was mainly involved in “senescence” and “apoptosis,” further confirming its role in regulating the occurrence and development of LPS by modulating the cell cycle progression and apoptosis. This study demonstrates that the elevated expression of LMNB2 is significantly associated with poor prognostic outcomes in LPS, suggesting that LMNB2 holds high potential as a new biomarker for LPS. This study is designed to elucidate the potential mechanism of LMNB2-mediated LPS progression, with the prospect of improving therapeutic development by identifying LMNB2 as a promising prognostic biomarker for LPS.

Deregulation of dicer and mir-155 expression in liposarcoma.

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versus normal fat. The tumor samples from LPS patients showed a significantly lower Dicer expression versus normal adipose tissue, while Drosha levels did not differ. Concerning mir155 expression levels, our results demonstrated a significant mir-155 up-regulation in all LPS subtypes versus normal adipose tissue except for WDLS. These findings demonstrate for the first time that Dicer is deregulated in LPS and show that mir-155 is differentially expressed in LPS subgroups and it could be a promising tool to improve LPS disease stratification and differential diagnosis.